T0	KEYPHRASE-NOTYPES 0 3	LNB
T1	KEYPHRASE-NOTYPES 8 20	inmany cases
T2	KEYPHRASE-NOTYPES 36 69	appropriate antimicrobial therapy
T3	KEYPHRASE-NOTYPES 78 98	clinical improvement
T4	KEYPHRASE-NOTYPES 116 136	antibiotic treatment
T5	KEYPHRASE-NOTYPES 145 161	evidence
T6	KEYPHRASE-NOTYPES 170 189	direct contribution
T7	KEYPHRASE-NOTYPES 193 194	B
T8	KEYPHRASE-NOTYPES 211 231	disease pathogenesis
T9	KEYPHRASE-NOTYPES 246 265	chronic persistence
T10	KEYPHRASE-NOTYPES 271 292	frequent reoccurrence
T11	KEYPHRASE-NOTYPES 296 299	LNB
T12	KEYPHRASE-NOTYPES 308 315	ability
T13	KEYPHRASE-NOTYPES 319 320	B
T14	KEYPHRASE-NOTYPES 346 361	multiple cycles
T15	KEYPHRASE-NOTYPES 365 385	antibiotic treatment
T16	KEYPHRASE-NOTYPES 417 426	formation
T17	KEYPHRASE-NOTYPES 430 437	biofilm
T18	KEYPHRASE-NOTYPES 441 473	biofilmlike protective structure
T19	KEYPHRASE-NOTYPES 491 508	different studies
T20	KEYPHRASE-NOTYPES 525 526	B
T21	KEYPHRASE-NOTYPES 551 562	fromamotile
T22	KEYPHRASE-NOTYPES 568 585	stationary status
T23	KEYPHRASE-NOTYPES 600 605	cells
T24	KEYPHRASE-NOTYPES 628 642	biofilm matrix
T25	KEYPHRASE-NOTYPES 649 650	B
T26	KEYPHRASE-NOTYPES 713 740	human infected skin tissues
T27	KEYPHRASE-NOTYPES 757 767	structures
T28	KEYPHRASE-NOTYPES 776 805	different mucopolysaccharides
T29	KEYPHRASE-NOTYPES 830 847	extracellular DNA
T30	KEYPHRASE-NOTYPES 852 859	calcium
T31	KEYPHRASE-NOTYPES 875 890	typical markers
T32	KEYPHRASE-NOTYPES 894 901	biofilm
T33	KEYPHRASE-NOTYPES 912 920	presence
T34	KEYPHRASE-NOTYPES 924 931	biofilm
T35	KEYPHRASE-NOTYPES 948 956	low rate
T36	KEYPHRASE-NOTYPES 969 978	detection
T37	KEYPHRASE-NOTYPES 986 991	blood
T38	KEYPHRASE-NOTYPES 995 1012	infected patients
T39	KEYPHRASE-NOTYPES 1028 1035	ability
T40	KEYPHRASE-NOTYPES 1043 1054	spirochetes
T41	KEYPHRASE-NOTYPES 1068 1089	host immune systemand
T42	KEYPHRASE-NOTYPES 1101 1119	antibiotic therapy
